← Back to Screener
Twist Bioscience Corporation Common Stock (TWST)
Price$69.22
Value ScoreD
Growth ScoreB
Momentum ScoreA
Favorite Metrics
Price vs S&P 500 (26W)108.32%
Price vs S&P 500 (4W)21.77%
VGM Score62.99
Market Capitalization$4.31B
All Metrics
Book Value / Share (Quarterly)$7.32
P/TBV (Annual)3.70x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)22.75%
Cash Flow / Share (Quarterly)$-1.61
Price vs S&P 500 (YTD)110.06%
Gross Margin (TTM)52.07%
Net Profit Margin (TTM)-19.85%
EPS (TTM)$-1.33
10-Day Avg Trading Volume1.73M
EPS Excl Extra (TTM)$-1.33
Revenue Growth (5Y)33.11%
EPS (Annual)$-1.30
ROI (Annual)-16.42%
Gross Margin (Annual)50.72%
Net Profit Margin (5Y Avg)-78.56%
Cash / Share (Quarterly)$2.76
Revenue Growth QoQ (YoY)19.31%
ROA (Last FY)-12.10%
Revenue Growth TTM (YoY)17.77%
EBITD / Share (TTM)$-1.87
ROE (5Y Avg)-29.44%
Operating Margin (TTM)-33.90%
Cash Flow / Share (Annual)$-1.25
P/B Ratio9.47x
P/B Ratio (Quarterly)6.40x
Net Income / Employee (Annual)$-79,300
EV / Revenue (TTM)10.23x
Net Interest Coverage (TTM)-235.67x
ROA (TTM)-12.51%
EPS Incl Extra (Annual)$-1.30
Current Ratio (Annual)3.64x
Quick Ratio (Quarterly)1.97x
3-Month Avg Trading Volume1.40M
52-Week Price Return128.22%
Revenue / Employee (TTM)$418,300
Tangible BV / Share (Quarterly)$7.11
P/S Ratio (Annual)11.45x
Asset Turnover (Annual)0.59x
52-Week High$80.50
Operating Margin (5Y Avg)-82.17%
EPS Excl Extra (Annual)$-1.30
CapEx CAGR (5Y)23.19%
Tangible BV CAGR (5Y)6.46%
26-Week Price Return116.24%
Quick Ratio (Annual)3.17x
13-Week Price Return42.25%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)2.70x
Enterprise Value$4.19B
Revenue / Share Growth (5Y)22.33%
Asset Turnover (TTM)0.63x
Book Value / Share Growth (5Y)0.91%
Revenue / Employee (Annual)$384,600
Inventory Turnover (Annual)7.08x
Pretax Margin (Annual)-20.43%
Cash / Share (Annual)$3.83
3-Month Return Std Dev74.52%
Gross Margin (5Y Avg)42.07%
Net Income / Employee (TTM)$-83,000
ROE (Last FY)-16.42%
Net Interest Coverage (Annual)-801.00x
EPS Basic Excl Extra (Annual)$-1.30
Receivables Turnover (TTM)7.18x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.33
Receivables Turnover (Annual)8.19x
ROI (TTM)-17.46%
P/S Ratio (TTM)10.53x
Pretax Margin (5Y Avg)-79.70%
Revenue / Share (Annual)$6.30
Tangible BV / Share (Annual)$7.58
Price vs S&P 500 (52W)103.86%
Year-to-Date Return118.22%
5-Day Price Return2.00%
EPS Normalized (Annual)$-1.30
ROA (5Y Avg)-23.35%
Net Profit Margin (Annual)-20.63%
Month-to-Date Return3.51%
Cash Flow / Share (TTM)$-3.08
EBITD / Share (Annual)$-1.05
Operating Margin (Annual)-23.21%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-29.42%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.33
P/TBV (Quarterly)6.59x
P/B Ratio (Annual)3.59x
Inventory Turnover (TTM)7.22x
Pretax Margin (TTM)-19.67%
Book Value / Share (Annual)$7.80
Price vs S&P 500 (13W)34.00%
Beta2.19x
Revenue / Share (TTM)$6.64
ROE (TTM)-17.46%
52-Week Low$23.30
vGradeD
gGradeB
mGradeA
vgmGradeB
Show chart for
Earnings Surprise History
Q2 26-0.59est. -0.49
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.24
4.24
4.24
4.31
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
TWSTTwist Bioscience Corporation Common Stock | D | B | A | $69.22 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Twist Bioscience Corp develops a semiconductor-based DNA synthesis platform that manufactures synthetic DNA on silicon, enabling faster production and lower costs than traditional methods. This proprietary technology supports high-throughput, cost-effective synthesis and accelerates innovation across research and development. The company generates revenue from three geographic regions—Americas, EMEA, and APAC—with the majority coming from North America.